Dr. Reddy's Laboratories Limited — Results, 24-01-2025: Integrated Filing- Financial

Dr. Reddy's Laboratories Ltd. has announced a board meeting to discuss its financial results for the quarter and nine-month period ending December 31, 2024. The consolidated revenue grew to ₹83,586 million, up from ₹72,148 million year-on-year, reflecting strong performance, particularly in the Global Generics segment. Notably, the company recognized a milestone payment of ₹1,266 million from a U.S. FDA approval as part of its Others segment. However, there was an impairment charge related to Haloette® totaling ₹907 million, stemming from procurement constraints. This release is likely to enhance investor confidence due to the positive revenue trajectory, although risks remain from ongoing regulatory scrutiny and market conditions.